-
-
Overview
-
Please contact us at for specific academic pricing.
Background
CNQX is a potent and competitive antagonist for AMPA/kainate receptors.
Superfusion of hippocampal slices and CNQX (2-5 μM) reversibly blocks Schaffer collaterals and mossy fiber excitatory post-synaptic potentials (EPSP), and also retains fast and slow GABA-mediated inhibitory effects[1].
Ten minutes before the test, CNQX (0.5 or 1.25 μg) is bilaterally infused into the amygdala or dorsal hippocampus, which partially prevented the expression of hypotensive avoidance in rats at 24 h after training. At a dose of 0.5 μg, CNQX causes complete blockade[2].[1]. Neuman R S, Ben-Ari Y, Gho M, et al. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the hippocampus in vitro. Neuroscience Letters, 1988, 92(1): 64-68.
[2]. Kim M, Campeau S, Falls W A, et al. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol, 1993, 59(1): 5-8.
-
- Properties
- Reference
-
Overview